N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275

  • Bioorg Med Chem Lett. 2009 Jul 1;19(13):3493-7. doi: 10.1016/j.bmcl.2009.05.011.
Michael Siu  1 ,  Theodore O Johnson ,  Yong Wang ,  Sajiv K Nair ,  Wendy D Taylor ,  Stephan J Cripps ,  Jean J Matthews ,  Martin P Edwards ,  Thomas A Pauly ,  Jacques Ermolieff ,  Arturo Castro ,  Natilie A Hosea ,  Amy LaPaglia ,  Andrea N Fanjul ,  Jennifer E Vogel
Affiliations
  • 1. Discovery Chemistry, Pfizer Global Research and Development, 10770 Science Center Drive, San Diego, CA 92121, United States. [email protected]
PMID: 19473839 DOI: 10.1016/j.bmcl.2009.05.011
Abstract

N-(Pyridin-2-yl) arylsulfonamides are identified as inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1), an enzyme that catalyzes the reduction of the glucocorticoid cortisone to cortisol. Dysregulation of glucocorticoids has been implicated in the pathogenesis of diabetes and the metabolic syndrome. In this Letter, we present the development of an initial lead to an efficient ligand with improved physiochemical properties using a deletion strategy. This strategy allowed for further optimization of potency leading to the discovery of the clinical candidate PF-915275.

Products